首页 > 最新文献

Medicina clinica (English ed.)最新文献

英文 中文
Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy 抗血小板疗法围术期和围术期管理不当的发生率和临床影响
Pub Date : 2024-10-09 DOI: 10.1016/j.medcle.2024.04.017
María Anguita-Gámez , David Vivas , Raquel Ferrandis , Rafael González-Manzanares , Manuel Anguita , María Asunción Esteve-Pastor , Marysol Echeverri , Jesús Igualada , Isabel Egocheaga , Beatriz Nozal-Mateo , Ane Abad-Motos , Elena Figuero , Nuria Bouzó-Molina , Teresa Lozano , Carlos Álvarez-Ortega , Javier Torres , María José Descalzo , Juan Carlos Catalá , Enrique Martín-Rioboo , Alejandra Molines , Francisco Marín

Background and aims

There is little evidence on the impact of current recommendations on the use of antiplatelet therapy during the perioperative and periprocedural period in our setting. The aim of this study was to analyze the incidence and clinical impact of inappropriate use of antiplatelet therapy in a population of patients undergoing surgery or a diagnostic or therapeutic procedure in “real life” in Spain.

Methods

A prospective multicenter observational study of patients treated with antiplatelet agents requiring intervention was conducted. The incidence of thrombotic and hemorrhagic events at 30 days was analyzed according to peri-intervention management of antiplatelet therapy.

Results

We included 643 patients (31.9% women, 39.0% over 75 years of age), most of them (87.7%) receiving aspirin as antiplatelet therapy at a dose of 100 mg/day. Indications for antiplatelet therapy were ischemic heart disease (44.9%), cerebrovascular disease (21.7%), and peripheral vascular disease (23.0%). Ischemic risk was low in 74.3%, while 51.6% had a low bleeding risk of the intervention. Periprocedural management was considered appropriate in 61.7% of cases. 30-day incidence of the combined primary endpoint of thrombotic events and major bleeding (12.1% versus 5.0%; p = 0.002) and 30-day mortality (5.2% versus 1.5%; p = 0.008) were significantly higher in patients with inappropriate periprocedural management of antiplatelet agents.

Conclusions

Despite current recommendations for the use of antiplatelet drugs in the perioperative/periprocedural period, their implementation in the “real world” remains low. Inappropriate use is associated with an increased incidence of adverse events, both thrombotic and hemorrhagic.
背景和目的在我们的环境中,几乎没有证据表明目前的建议对围手术期和围手术期使用抗血小板疗法的影响。本研究旨在分析在西班牙 "真实生活 "中接受手术或诊断或治疗程序的患者中不适当使用抗血小板疗法的发生率和临床影响。结果我们纳入了 643 名患者(31.9% 为女性,39.0% 年龄超过 75 岁),其中大多数(87.7%)接受阿司匹林作为抗血小板疗法,剂量为 100 毫克/天。抗血小板治疗的适应症为缺血性心脏病(44.9%)、脑血管疾病(21.7%)和外周血管疾病(23.0%)。74.3%的患者缺血风险较低,51.6%的患者介入治疗的出血风险较低。61.7%的病例的围手术期管理被认为是适当的。在抗血小板药物围手术期管理不当的患者中,血栓事件和大出血的30天综合主要终点发生率(12.1%对5.0%;P = 0.002)和30天死亡率(5.2%对1.5%;P = 0.008)明显更高。使用不当会增加血栓性和出血性不良事件的发生率。
{"title":"Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy","authors":"María Anguita-Gámez ,&nbsp;David Vivas ,&nbsp;Raquel Ferrandis ,&nbsp;Rafael González-Manzanares ,&nbsp;Manuel Anguita ,&nbsp;María Asunción Esteve-Pastor ,&nbsp;Marysol Echeverri ,&nbsp;Jesús Igualada ,&nbsp;Isabel Egocheaga ,&nbsp;Beatriz Nozal-Mateo ,&nbsp;Ane Abad-Motos ,&nbsp;Elena Figuero ,&nbsp;Nuria Bouzó-Molina ,&nbsp;Teresa Lozano ,&nbsp;Carlos Álvarez-Ortega ,&nbsp;Javier Torres ,&nbsp;María José Descalzo ,&nbsp;Juan Carlos Catalá ,&nbsp;Enrique Martín-Rioboo ,&nbsp;Alejandra Molines ,&nbsp;Francisco Marín","doi":"10.1016/j.medcle.2024.04.017","DOIUrl":"10.1016/j.medcle.2024.04.017","url":null,"abstract":"<div><h3>Background and aims</h3><div>There is little evidence on the impact of current recommendations on the use of antiplatelet therapy during the perioperative and periprocedural period in our setting. The aim of this study was to analyze the incidence and clinical impact of inappropriate use of antiplatelet therapy in a population of patients undergoing surgery or a diagnostic or therapeutic procedure in “real life” in Spain.</div></div><div><h3>Methods</h3><div>A prospective multicenter observational study of patients treated with antiplatelet agents requiring intervention was conducted. The incidence of thrombotic and hemorrhagic events at 30 days was analyzed according to peri-intervention management of antiplatelet therapy.</div></div><div><h3>Results</h3><div>We included 643 patients (31.9% women, 39.0% over 75 years of age), most of them (87.7%) receiving aspirin as antiplatelet therapy at a dose of 100<!--> <!-->mg/day. Indications for antiplatelet therapy were ischemic heart disease (44.9%), cerebrovascular disease (21.7%), and peripheral vascular disease (23.0%). Ischemic risk was low in 74.3%, while 51.6% had a low bleeding risk of the intervention. Periprocedural management was considered appropriate in 61.7% of cases. 30-day incidence of the combined primary endpoint of thrombotic events and major bleeding (12.1% versus 5.0%; <em>p</em> <!-->=<!--> <!-->0.002) and 30-day mortality (5.2% versus 1.5%; <em>p</em> <!-->=<!--> <!-->0.008) were significantly higher in patients with inappropriate periprocedural management of antiplatelet agents.</div></div><div><h3>Conclusions</h3><div>Despite current recommendations for the use of antiplatelet drugs in the perioperative/periprocedural period, their implementation in the “real world” remains low. Inappropriate use is associated with an increased incidence of adverse events, both thrombotic and hemorrhagic.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 336-343"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Raynaud phenomenon in a baseball player 棒球运动员的雷诺现象
Pub Date : 2024-10-09 DOI: 10.1016/j.medcle.2023.12.030
Kiyomi Yoshimoto , Hiromasa Kawashima , Jun Nakakita , Kenji Nishio
{"title":"Raynaud phenomenon in a baseball player","authors":"Kiyomi Yoshimoto ,&nbsp;Hiromasa Kawashima ,&nbsp;Jun Nakakita ,&nbsp;Kenji Nishio","doi":"10.1016/j.medcle.2023.12.030","DOIUrl":"10.1016/j.medcle.2023.12.030","url":null,"abstract":"","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Page e79"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of physical activity, sedentary time, and fitness with cardiovascular risk and atherosclerosis over 3 years in women with systemic lupus erythematosus 系统性红斑狼疮女性患者三年内的体力活动、久坐时间和体能与心血管风险和动脉粥样硬化的关系
Pub Date : 2024-10-09 DOI: 10.1016/j.medcle.2024.04.018
Blanca Gavilán-Carrera , Elena Martínez-Rosales , Clara Palacios-Morenilla , Antonio Díaz-Chamorro , Alberto Soriano-Maldonado , José Antonio Vargas-Hitos

Introduction

Cardiovascular (CV) diseases are among the main causes of death in systemic lupus erythematosus (SLE). Physical activity (PA) and fitness are potential protective factors against the progression of CV risk factors and atherosclerosis.

Aim

To analyze trends over time in PA, sedentary time (ST) and physical fitness and their associations of with traditional and novel markers of CV risk and subclinical atherosclerosis in women with SLE over a 3-year follow-up period.

Methods

In this exploratory study, 77 White Hispanic women with SLE (43.3 ± 13.8 years) with mild disease activity were followed after 3 years (n = 44). HDL and LDL cholesterol (blood samples), BMI and muscle mass (stadiometer and bioimpedance device), blood pressure (BP), pulse wave velocity (PWV, Mobil-O-Graph® monitor), carotid plaques and intima–media thickness (General Electric Medical Systems, LOGQ-6 model) were assessed. PA and ST were measured using triaxial accelerometers. Physical fitness was assessed with the back-scratch, handgrip strength, 30-s chair stand, and 6-min walk, tests.

Results

After 3 years, LDL-c (estimated mean change [est] = 13.77 mg/dL) and PWV (0.13 m/s) increased while diastolic BP (−2.80 mmHG) decreased (all, p < 0.05). In mixed models, 6-min walk test was positively associated with HDL-c (est = 0.07); back scratch (est = 0.33) and chair-stand (est = 1.19) tests were positively associated with systolic BP (all, p < 0.05). No other trends or associations over time were identified (all, p > 0.05).

Conclusions

PA, ST, fitness, and most studied CV risk factors remained stable over time, with only marginal changes in LDL-c, PWV, and diastolic BP. Overall, PA and ST were not longitudinally associated with CV risk factors and subclinical atherosclerosis and contradictory weak associations were found for physical fitness.
导言心血管疾病是系统性红斑狼疮(SLE)患者的主要死因之一。方法在这项探索性研究中,对 77 名患有系统性红斑狼疮(43.3 ± 13.8 岁)且疾病活动轻微的西班牙裔白人女性患者(n = 44)进行了为期 3 年的随访。对高密度脂蛋白和低密度脂蛋白胆固醇(血样)、体重指数和肌肉质量(体重计和生物阻抗仪)、血压(BP)、脉搏波速度(PWV,Mobil-O-Graph® 监测器)、颈动脉斑块和内膜中层厚度(通用电气医疗系统公司,LOGQ-6 型)进行了评估。使用三轴加速度计测量 PA 和 ST。结果3年后,低密度脂蛋白胆固醇(估计平均变化[est] = 13.77 mg/dL)和脉搏波速度(0.13 m/s)增加,而舒张压(-2.80 mmHG)下降(所有数据,p < 0.05)。在混合模型中,6 分钟步行测试与 HDL-c 呈正相关(EST = 0.07);背划(EST = 0.33)和椅子站立(EST = 1.19)测试与收缩压呈正相关(均为 p <;0.05)。结论随着时间的推移,PA、ST、体能和大多数研究的心血管风险因素保持稳定,LDL-c、脉搏波速度和舒张压仅有微小变化。总体而言,PA 和 ST 与冠状动脉风险因素和亚临床动脉粥样硬化没有纵向联系,而体能则存在相互矛盾的微弱联系。
{"title":"Associations of physical activity, sedentary time, and fitness with cardiovascular risk and atherosclerosis over 3 years in women with systemic lupus erythematosus","authors":"Blanca Gavilán-Carrera ,&nbsp;Elena Martínez-Rosales ,&nbsp;Clara Palacios-Morenilla ,&nbsp;Antonio Díaz-Chamorro ,&nbsp;Alberto Soriano-Maldonado ,&nbsp;José Antonio Vargas-Hitos","doi":"10.1016/j.medcle.2024.04.018","DOIUrl":"10.1016/j.medcle.2024.04.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Cardiovascular (CV) diseases are among the main causes of death in systemic lupus erythematosus (SLE). Physical activity (PA) and fitness are potential protective factors against the progression of CV risk factors and atherosclerosis.</div></div><div><h3>Aim</h3><div>To analyze trends over time in PA, sedentary time (ST) and physical fitness and their associations of with traditional and novel markers of CV risk and subclinical atherosclerosis in women with SLE over a 3-year follow-up period.</div></div><div><h3>Methods</h3><div>In this exploratory study, 77 White Hispanic women with SLE (43.3<!--> <!-->±<!--> <!-->13.8 years) with mild disease activity were followed after 3 years (<em>n</em> <!-->=<!--> <!-->44). HDL and LDL cholesterol (blood samples), BMI and muscle mass (stadiometer and bioimpedance device), blood pressure (BP), pulse wave velocity (PWV, Mobil-O-Graph® monitor), carotid plaques and intima–media thickness (General Electric Medical Systems, LOGQ-6 model) were assessed. PA and ST were measured using triaxial accelerometers. Physical fitness was assessed with the back-scratch, handgrip strength, 30-s chair stand, and 6-min walk, tests.</div></div><div><h3>Results</h3><div>After 3 years, LDL-c (estimated mean change [est]<!--> <!-->=<!--> <!-->13.77<!--> <!-->mg/dL) and PWV (0.13<!--> <!-->m/s) increased while diastolic BP (−2.80<!--> <!-->mmHG) decreased (all, <em>p</em> <!-->&lt;<!--> <!-->0.05). In mixed models, 6-min walk test was positively associated with HDL-c (est<!--> <!-->=<!--> <!-->0.07); back scratch (est<!--> <!-->=<!--> <!-->0.33) and chair-stand (est<!--> <!-->=<!--> <!-->1.19) tests were positively associated with systolic BP (all, <em>p</em> <!-->&lt;<!--> <!-->0.05). No other trends or associations over time were identified (all, <em>p</em> <!-->&gt;<!--> <!-->0.05).</div></div><div><h3>Conclusions</h3><div>PA, ST, fitness, and most studied CV risk factors remained stable over time, with only marginal changes in LDL-c, PWV, and diastolic BP. Overall, PA and ST were not longitudinally associated with CV risk factors and subclinical atherosclerosis and contradictory weak associations were found for physical fitness.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 327-335"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of renal damage in Wilson's disease—Detailed analysis of 20 Chinese cases 威尔逊氏病肾损害的特征--20 例中国病例的详细分析
Pub Date : 2024-10-09 DOI: 10.1016/j.medcle.2024.02.019
Shan Jin , Zhengzhe Sun , Xiang Fang , Wenming Yang
<div><h3>Objective</h3><div>Copper metabolism disorder disease is thought to contribute to renal symptoms in Wilson's disease (WD). Nonetheless, there remains limited knowledge regarding the precise characteristics of renal damage in individuals with Wilson's disease, encompassing clinical presentations, biochemical indicators, imaging findings, and renal histopathological alterations.</div></div><div><h3>Methods</h3><div>In this study, 20 patients diagnosed with Wilson's disease and renal involvement were enrolled in our hospital. These patients met the validated European criteria for Wilson's disease, and those with primary kidney disease or secondary renal damage caused by other underlying conditions were excluded.</div><div>The baseline data of patients were collected. Various biochemical and hematological parameters were monitored. Biochemical examinations were measured using an automatic biochemistry analyzer, blood routines were tested by flow cytometry analysis, 24-h urine copper was tested by atomic absorption spectrophotometer. Besides, CER was measured by turbidimetric immunoassay with a Hitachi 7020 automatic biochemical analyzer (the intraplate and interplate coefficients of variation were 2.7% and 5.13% respectively). Copper oxidase was tested by colorimetric method using p-phenylenediamine hydrochloride (the intraplate and interplate coefficients of variation were both <10%). Diagnostic criteria for Wilson's disease and kidney damage were established based on the European Association for the Study of the Liver (EASL) and CKD Epidemiology Collaboration guidelines, respectively. Statistical analysis was carried out using <em>t</em>-tests and <em>χ</em><sup>2</sup> tests in SPSS 22.0 software. Significant differences were considered when <em>P</em> <!--><<!--> <!-->0.05.</div></div><div><h3>Results</h3><div>In those patients with Wilson's disease-related renal damage, edema, gross hematuria, oliguria, and lumbar pain were present in most patients. Microscopic haematuria and proteinuria were also observed in 19 patients. Compared to patients without renal involvement, those with renal complications exhibited a significant increase in white blood cell (WBC) and neutrophil counts (<em>P</em> <!--><<!--> <!-->0.05). Additionally, patients with renal damage showed a noteworthy rise in both diastolic and systolic blood pressure, along with a significant reduction in hemoglobin levels (<em>P</em> <!--><<!--> <!-->0.05). Color Doppler ultrasound results revealed diffuse lesions in both kidneys in 12 patients, renal cysts were identified in 5 patients, and 2 patients exhibited abnormal renal blood flow signals. Meanwhile, varying degrees of IgA, IgM, IgG-based immunoglobulins, complement C3 and C1q deposition in the glomerular mesangial area were detected by immunofluorescence. Furthermore, renal puncture biopsy results revealed a spectrum of findings, including minimal change nephrosis in 1 case, IgA nephropathy in 3 cases, atypic
目的铜代谢紊乱疾病被认为是导致威尔逊氏病(WD)肾脏症状的原因之一。然而,人们对威尔逊氏病患者肾脏损害的确切特征,包括临床表现、生化指标、影像学检查结果和肾脏组织病理学改变的了解仍然有限。这些患者均符合欧洲威尔逊氏病的有效标准,并排除了原发性肾脏疾病或由其他基础疾病引起的继发性肾损害的患者。收集了患者的基线数据,监测了各种生化指标和血液指标。生化检查采用自动生化分析仪,血液常规采用流式细胞术分析,24 小时尿铜采用原子吸收分光光度计。此外,还使用日立 7020 自动生化分析仪通过比浊免疫测定法测定了 CER(板内变异系数为 2.7%,板间变异系数为 5.13%)。铜氧化酶采用对苯二胺盐酸盐比色法检测(板内和板间变异系数均为 10%)。威尔逊氏病和肾损伤的诊断标准分别根据欧洲肝脏研究协会(EASL)和 CKD 流行病学协作组指南制定。统计分析采用 SPSS 22.0 软件中的 t 检验和 χ2 检验。结果在威尔逊氏病相关肾损害患者中,大多数患者出现水肿、毛细血尿、少尿和腰痛。19名患者还出现了镜下血尿和蛋白尿。与没有肾脏受累的患者相比,肾脏并发症患者的白细胞(WBC)和中性粒细胞计数显著增加(P < 0.05)。此外,肾脏受损患者的舒张压和收缩压均明显升高,血红蛋白水平显著下降(P < 0.05)。彩色多普勒超声结果显示,12 名患者的双肾出现弥漫性病变,5 名患者发现肾囊肿,2 名患者出现肾血流信号异常。同时,免疫荧光检测到肾小球系膜区有不同程度的 IgA、IgM、IgG 类免疫球蛋白、补体 C3 和 C1q 沉积。此外,肾穿刺活检结果显示了一系列结果,包括 1 例微小病变肾病、3 例 IgA 肾病、2 例非典型膜性增生性肾病和 1 例局灶节段性肾小球硬化。根据潜在的发病机制,与威尔逊氏病相关的肾损伤可分为原发性和继发性两种。为了延缓肾功能损害的进展,必须尽早进行肾活检病理检查,以明确损害类型并采取适当的治疗措施。
{"title":"Characterization of renal damage in Wilson's disease—Detailed analysis of 20 Chinese cases","authors":"Shan Jin ,&nbsp;Zhengzhe Sun ,&nbsp;Xiang Fang ,&nbsp;Wenming Yang","doi":"10.1016/j.medcle.2024.02.019","DOIUrl":"10.1016/j.medcle.2024.02.019","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Copper metabolism disorder disease is thought to contribute to renal symptoms in Wilson's disease (WD). Nonetheless, there remains limited knowledge regarding the precise characteristics of renal damage in individuals with Wilson's disease, encompassing clinical presentations, biochemical indicators, imaging findings, and renal histopathological alterations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this study, 20 patients diagnosed with Wilson's disease and renal involvement were enrolled in our hospital. These patients met the validated European criteria for Wilson's disease, and those with primary kidney disease or secondary renal damage caused by other underlying conditions were excluded.&lt;/div&gt;&lt;div&gt;The baseline data of patients were collected. Various biochemical and hematological parameters were monitored. Biochemical examinations were measured using an automatic biochemistry analyzer, blood routines were tested by flow cytometry analysis, 24-h urine copper was tested by atomic absorption spectrophotometer. Besides, CER was measured by turbidimetric immunoassay with a Hitachi 7020 automatic biochemical analyzer (the intraplate and interplate coefficients of variation were 2.7% and 5.13% respectively). Copper oxidase was tested by colorimetric method using p-phenylenediamine hydrochloride (the intraplate and interplate coefficients of variation were both &lt;10%). Diagnostic criteria for Wilson's disease and kidney damage were established based on the European Association for the Study of the Liver (EASL) and CKD Epidemiology Collaboration guidelines, respectively. Statistical analysis was carried out using &lt;em&gt;t&lt;/em&gt;-tests and &lt;em&gt;χ&lt;/em&gt;&lt;sup&gt;2&lt;/sup&gt; tests in SPSS 22.0 software. Significant differences were considered when &lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;In those patients with Wilson's disease-related renal damage, edema, gross hematuria, oliguria, and lumbar pain were present in most patients. Microscopic haematuria and proteinuria were also observed in 19 patients. Compared to patients without renal involvement, those with renal complications exhibited a significant increase in white blood cell (WBC) and neutrophil counts (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.05). Additionally, patients with renal damage showed a noteworthy rise in both diastolic and systolic blood pressure, along with a significant reduction in hemoglobin levels (&lt;em&gt;P&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.05). Color Doppler ultrasound results revealed diffuse lesions in both kidneys in 12 patients, renal cysts were identified in 5 patients, and 2 patients exhibited abnormal renal blood flow signals. Meanwhile, varying degrees of IgA, IgM, IgG-based immunoglobulins, complement C3 and C1q deposition in the glomerular mesangial area were detected by immunofluorescence. Furthermore, renal puncture biopsy results revealed a spectrum of findings, including minimal change nephrosis in 1 case, IgA nephropathy in 3 cases, atypic","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 360-366"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Condyloma lata of the tongue 舌尖锐湿疣
Pub Date : 2024-10-09 DOI: 10.1016/j.medcle.2024.01.043
Víctor García-Rodríguez , Nuria Setó-Torrent , Montse Salleras-Redonnet
{"title":"Condyloma lata of the tongue","authors":"Víctor García-Rodríguez ,&nbsp;Nuria Setó-Torrent ,&nbsp;Montse Salleras-Redonnet","doi":"10.1016/j.medcle.2024.01.043","DOIUrl":"10.1016/j.medcle.2024.01.043","url":null,"abstract":"","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Page e80"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review 西班牙免疫力低下患者中 COVID-19 变体 omicron 的负担:系统回顾
Pub Date : 2024-09-25 DOI: 10.1016/j.medcle.2024.09.001
Raúl Ortiz-de-Lejarazu , Borja Quiroga Gili , Alberto López García
After the COVID-19 pandemic, the Omicron variant of the SARS-CoV-2 virus became the dominant lineage in Spain in 2022. Although it possesses a milder pathogenicity than previous variants, it still poses a high risk of causing severe COVID-19 for immunocompromised populations.
A systematic review was conducted to assess the burden of COVID-19 in Spain among immunocompromised patients during the Omicron predominance (1/04/2022–1/04/2023), using PubMed, Cochrane Library, and EPICOVIDEHA between May and July 2023.
The search retrieved 217 articles, of which a total of 5 were included. Upon analysis, it was observed that immunocompromised patients during the Omicron lineage predominance continue to exhibit higher rates of hospitalizations, ICU admissions, and mortality compared to the general population affected by COVID-19. Although the pandemic has ended, the risk persists for immunocompromised individuals.
COVID-19 大流行之后,SARS-CoV-2 病毒的 Omicron 变种于 2022 年成为西班牙的主要变种。在 2023 年 5 月至 7 月期间,我们利用 PubMed、Cochrane Library 和 EPICOVIDEHA 等网站进行了一项系统性研究,以评估在 Omicron 流行期间(2022 年 4 月 1 日-2023 年 4 月 1 日)西班牙免疫力低下的患者中 COVID-19 的负担。经分析发现,与受 COVID-19 影响的普通人群相比,在 Omicron 系占主导地位期间的免疫力低下患者的住院率、重症监护室入院率和死亡率仍然较高。虽然大流行已经结束,但免疫力低下者的风险依然存在。
{"title":"Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review","authors":"Raúl Ortiz-de-Lejarazu ,&nbsp;Borja Quiroga Gili ,&nbsp;Alberto López García","doi":"10.1016/j.medcle.2024.09.001","DOIUrl":"10.1016/j.medcle.2024.09.001","url":null,"abstract":"<div><div>After the COVID-19 pandemic, the Omicron variant of the SARS-CoV-2 virus became the dominant lineage in Spain in 2022. Although it possesses a milder pathogenicity than previous variants, it still poses a high risk of causing severe COVID-19 for immunocompromised populations.</div><div>A systematic review was conducted to assess the burden of COVID-19 in Spain among immunocompromised patients during the Omicron predominance (1/04/2022–1/04/2023), using PubMed, Cochrane Library, and EPICOVIDEHA between May and July 2023.</div><div>The search retrieved 217 articles, of which a total of 5 were included. Upon analysis, it was observed that immunocompromised patients during the Omicron lineage predominance continue to exhibit higher rates of hospitalizations, ICU admissions, and mortality compared to the general population affected by COVID-19. Although the pandemic has ended, the risk persists for immunocompromised individuals.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 347-359"},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142417984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Soluble urokinase type plasminogen activator receptor (suPAR) and mortality in acute pulmonary embolism 可溶性尿激酶型纤溶酶原激活物受体(suPAR)与急性肺栓塞的死亡率
Pub Date : 2024-09-24 DOI: 10.1016/j.medcle.2024.04.013
Crhistian-Mario Oblitas , Marina López-Rubio , Marta-Olimpia Lago-Rodríguez , Francisco Galeano-Valle , Mercedes García-Gámiz , Angielys Zamora-Trillo , Luis-Antonio Alvarez-Sala Walther , Pablo Demelo-Rodríguez

Introduction

The soluble urokinase-type plasminogen activator receptor (suPAR) potentially plays a role in immune-thrombosis, possibly by modulating plasmin activity or contributing to chemotaxis in a complex, poorly understood context. The role of suPAR levels in the short-term prognostic of patients with pulmonary embolism (PE) has not been evaluated.

Material and methods

This observational, prospective, single-center study enrolled consecutive patients aged 18 and above with confirmed acute symptomatic PE and no prior anticoagulant therapy. The primary objective was to assess the prognostic capacity of suPAR levels measured at the time of diagnosis in terms of mortality.

Results

Fifty-two patients, with a mean age of 73.8 years (±17), were included, with gender distribution evenly split at 50%. Seven (13.5%) patients died. The ROC curve for mortality yielded an AUC of 0.72 (95% CI 0.48–0.96), with an optimal suPAR cut-off of 5.5 ng/mL. Bivariate analysis for suPAR > 5.5 ng/mL was associated with a crude odds ratio of 10 (95% CI 1.63–61.27; p = 0.01) for 30-day mortality. Survival analysis showed a 30-day mortality hazard ratio of 8.33 (95% CI 1.69–40.99; p < 0.01).

Conclusion

suPAR emerges as a potential biomarker for short-term mortality prediction and holds the potential for enhanced stratification in patients with acute symptomatic PE.
导言可溶性尿激酶型纤溶酶原激活物受体(suPAR)可能在免疫血栓形成中发挥作用,可能通过调节纤溶酶原激活物的活性或促进趋化作用,其背景复杂且鲜为人知。这项观察性、前瞻性、单中心研究连续纳入了年龄在 18 岁及以上、确诊为急性无症状 PE 且之前未接受过抗凝剂治疗的患者。研究的主要目的是评估诊断时测定的 suPAR 水平对死亡率的预后能力。结果研究共纳入 52 例患者,平均年龄为 73.8 岁(±17)岁,男女比例各占 50%。七名患者(13.5%)死亡。死亡率 ROC 曲线的 AUC 为 0.72(95% CI 0.48-0.96),最佳 suPAR 临界值为 5.5 纳克/毫升。对 suPAR > 5.5 纳克/毫升的二元分析显示,30 天死亡率的粗略赔率为 10(95% CI 1.63-61.27;P = 0.01)。结论suPAR是预测短期死亡率的潜在生物标志物,具有对急性无症状PE患者进行强化分层的潜力。
{"title":"Soluble urokinase type plasminogen activator receptor (suPAR) and mortality in acute pulmonary embolism","authors":"Crhistian-Mario Oblitas ,&nbsp;Marina López-Rubio ,&nbsp;Marta-Olimpia Lago-Rodríguez ,&nbsp;Francisco Galeano-Valle ,&nbsp;Mercedes García-Gámiz ,&nbsp;Angielys Zamora-Trillo ,&nbsp;Luis-Antonio Alvarez-Sala Walther ,&nbsp;Pablo Demelo-Rodríguez","doi":"10.1016/j.medcle.2024.04.013","DOIUrl":"10.1016/j.medcle.2024.04.013","url":null,"abstract":"<div><h3>Introduction</h3><div>The soluble urokinase-type plasminogen activator receptor (suPAR) potentially plays a role in immune-thrombosis, possibly by modulating plasmin activity or contributing to chemotaxis in a complex, poorly understood context. The role of suPAR levels in the short-term prognostic of patients with pulmonary embolism (PE) has not been evaluated.</div></div><div><h3>Material and methods</h3><div>This observational, prospective, single-center study enrolled consecutive patients aged 18 and above with confirmed acute symptomatic PE and no prior anticoagulant therapy. The primary objective was to assess the prognostic capacity of suPAR levels measured at the time of diagnosis in terms of mortality.</div></div><div><h3>Results</h3><div>Fifty-two patients, with a mean age of 73.8 years (±17), were included, with gender distribution evenly split at 50%. Seven (13.5%) patients died. The ROC curve for mortality yielded an AUC of 0.72 (95% CI 0.48–0.96), with an optimal suPAR cut-off of 5.5<!--> <!-->ng/mL. Bivariate analysis for suPAR<!--> <!-->&gt;<!--> <!-->5.5<!--> <!-->ng/mL was associated with a crude odds ratio of 10 (95% CI 1.63–61.27; <em>p</em> <!-->=<!--> <!-->0.01) for 30-day mortality. Survival analysis showed a 30-day mortality hazard ratio of 8.33 (95% CI 1.69–40.99; <em>p</em> <!-->&lt;<!--> <!-->0.01).</div></div><div><h3>Conclusion</h3><div>suPAR emerges as a potential biomarker for short-term mortality prediction and holds the potential for enhanced stratification in patients with acute symptomatic PE.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 6","pages":"Pages 281-285"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative imaging study of patients with persistent olfactory dysfunction due to mild COVID-19 using structural and functional MRI 利用结构和功能磁共振成像对轻度 COVID-19 引起的持续性嗅觉功能障碍患者进行成像对比研究
Pub Date : 2024-09-24 DOI: 10.1016/j.medcle.2024.04.014
David Dylan García-Meléndez, Raquel Moreno Presa, Pilar Quintana Castro, Bárbara Serrano Calleja, Sara Rosenstone Calvo, María Isabel Morales-Casado

Introduction

Persistent post-COVID olfactory dysfunction continues to be studied due to the controversy in its pathophysiology and neuroimaging.

Materials and methods

The patients had confirmed mild COVID-19 infection with olfactory dysfunction of more than one month of evolution and they were compared to controls with normal olfaction, assessed using the Sniffin’ Sticks Olfactory Test and underwent brain, magnetic resonance imaging (MRI) of the olfactory bulb and olfactory function.

Results

A total of 8 patients and 2 controls participated. The average age of the patients was 34.5 years (SD 8.5), and that of the controls was 28.5 (SD 2.1). The average score in the patients’ olfactory test was 7.9 points (SD 2.2). In brain and olfactory bulb MRI tests, no morphological differences were found. When evaluated by functional MRI, none of the patients activated the entorhinal area in comparison to the controls, who did show activation at this level. Activation of secondary olfactory areas in cases and controls were as follows: orbitofrontal (25% vs 100%), basal ganglia (25% vs 50%) and insula (38% vs 0%) respectively.

Conclusions

There were no observed morphological changes in the brain MRI. Unlike the controls, none of the patients activated the entorhinal cortex in the olfactory functional MRI.
材料与方法 患者确诊为轻度 COVID-19 感染,并伴有超过一个月的嗅觉功能障碍,将他们与嗅觉正常的对照组进行比较,使用嗅棒嗅觉测试(Sniffin' Sticks Olfactory Test)进行评估,并对嗅球和嗅觉功能进行脑部磁共振成像(MRI)检查。患者的平均年龄为 34.5 岁(SD 8.5),对照组的平均年龄为 28.5 岁(SD 2.1)。患者的嗅觉测试平均分为 7.9 分(标准差为 2.2 分)。在大脑和嗅球核磁共振成像测试中,没有发现任何形态学差异。通过功能性核磁共振成像进行评估时,与对照组相比,患者均未激活内嗅区,而对照组则显示激活了内嗅区。病例和对照组的次级嗅区激活情况如下:眶额叶(25% vs 100%)、基底节(25% vs 50%)和岛叶(38% vs 0%)。与对照组不同的是,在嗅觉功能磁共振成像中,没有一名患者激活了内侧皮层。
{"title":"Comparative imaging study of patients with persistent olfactory dysfunction due to mild COVID-19 using structural and functional MRI","authors":"David Dylan García-Meléndez,&nbsp;Raquel Moreno Presa,&nbsp;Pilar Quintana Castro,&nbsp;Bárbara Serrano Calleja,&nbsp;Sara Rosenstone Calvo,&nbsp;María Isabel Morales-Casado","doi":"10.1016/j.medcle.2024.04.014","DOIUrl":"10.1016/j.medcle.2024.04.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Persistent post-COVID olfactory dysfunction continues to be studied due to the controversy in its pathophysiology and neuroimaging.</div></div><div><h3>Materials and methods</h3><div>The patients had confirmed mild COVID-19 infection with olfactory dysfunction of more than one month of evolution and they were compared to controls with normal olfaction, assessed using the Sniffin’ Sticks Olfactory Test and underwent brain, magnetic resonance imaging (MRI) of the olfactory bulb and olfactory function.</div></div><div><h3>Results</h3><div>A total of 8 patients and 2 controls participated. The average age of the patients was 34.5 years (SD 8.5), and that of the controls was 28.5 (SD 2.1). The average score in the patients’ olfactory test was 7.9 points (SD 2.2). In brain and olfactory bulb MRI tests, no morphological differences were found. When evaluated by functional MRI, none of the patients activated the entorhinal area in comparison to the controls, who did show activation at this level. Activation of secondary olfactory areas in cases and controls were as follows: orbitofrontal (25% vs 100%), basal ganglia (25% vs 50%) and insula (38% vs 0%) respectively.</div></div><div><h3>Conclusions</h3><div>There were no observed morphological changes in the brain MRI. Unlike the controls, none of the patients activated the entorhinal cortex in the olfactory functional MRI.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 6","pages":"Pages 286-290"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ifosfamide-induced acute kidney injury and confusional syndrome in a patient with diffuse large B-cell lymphoma 一名弥漫大 B 细胞淋巴瘤患者因伊福酰胺诱发的急性肾损伤和意识模糊综合征
Pub Date : 2024-09-24 DOI: 10.1016/j.medcle.2024.01.030
Thais Lizondo López , Andrea Rivero , Esther Carcelero San Martín
{"title":"Ifosfamide-induced acute kidney injury and confusional syndrome in a patient with diffuse large B-cell lymphoma","authors":"Thais Lizondo López ,&nbsp;Andrea Rivero ,&nbsp;Esther Carcelero San Martín","doi":"10.1016/j.medcle.2024.01.030","DOIUrl":"10.1016/j.medcle.2024.01.030","url":null,"abstract":"","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 6","pages":"Pages 308-309"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial aortic aneurysm: A case presentation 家族性主动脉瘤:病例介绍
Pub Date : 2024-09-24 DOI: 10.1016/j.medcle.2024.03.030
María Martínez-Avial Silva, Pablo Díez-Villanueva, Fernando Alfonso
{"title":"Familial aortic aneurysm: A case presentation","authors":"María Martínez-Avial Silva,&nbsp;Pablo Díez-Villanueva,&nbsp;Fernando Alfonso","doi":"10.1016/j.medcle.2024.03.030","DOIUrl":"10.1016/j.medcle.2024.03.030","url":null,"abstract":"","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"163 7","pages":"Pages 371-372"},"PeriodicalIF":0.0,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142418042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicina clinica (English ed.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1